Cytotoxic t lymphocyte (CTL) to macrophage ratio to predict survival in stage II-III melanoma: Validation in a second cohort. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...
Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.
Kanaph Therapeutics Inc. and Yungjin Pharmaceutical Co., Ltd. have presented tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of ...
Medshine Discovery Inc. has patented selenium-containing compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results